AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01391494 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 640Eu/0.5ml in children
Description: inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 12 children aged 3-11 years old on day 0, 14.
Study NCT01391494 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1280Eu/0.5ml (without adjuvant) in children
Description: inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 12 children aged 3-11 years old on day 0, 14.
Study NCT01391494 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: 0Eu/0.5ml in children
Description: 0Eu/0.5ml placebo in 24 children aged 3-11 years old on day 0, 14.
Study NCT01391494 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 160Eu/0.5ml in infants
Description: inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 24 infants aged 6-35 months old on day 0, 28.
Study NCT01391494 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 320Eu/0.5ml in infants
Description: inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 24 infants aged 6-35 months old on day 0, 28.
Study NCT01391494 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 640Eu/0.5ml in infants
Description: inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 24 infants aged 6-35 months old on day 0, 28.
Study NCT01391494 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1280Eu/0.5ml (without adjuvant) in infants
Description: inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 24 infants aged 6-35 months old on day 0, 28.
Study NCT01391494 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: 0Eu/0.5ml in infants
Description: 0Eu/0.5ml placebo in 48 infants aged 6-35 months old on day 0, 28.
Study NCT01366963 — intervention group
Intervention type: BEHAVIORAL
Intervention: Self-Administered Surveys
Description: Center for Epidemiologic Studies Depression Scale (CES-D) Cognitive-Somatic Anxiety Questionnaire (CSAQ) Subjective Neurocognitive Inventory (SNI)
Study NCT01283620 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: modified constraint induced movement therapy (mCIMT)
Description: The intervention group will receive usual care plus mCIMT. mCIMT consists of two components delivered in parallel: three 30 min therapy sessions/week focusing on progressively more difficult tasks performed with the arm/hand, and five hours/weekday of restraint of the unaffected upper limb. Each 30 min therapy session consists of using the affected upper limb in practicing 4-5 functionally relevant tasks.
Study NCT01283620 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual and Customary Care
Description: Patients in this arm will receive usual care dose-matched to the experimental care group. Usual care will consist of occupational and physiotherapy intervention focused on affected upper limb range of motion (i.e., active range of motion incorporated into functional tasks such as reaching), strengthening (i.e., upper limb resisted exercise), manual dexterity exercises (i.e., grasp and release, stacking cones), and general aerobic conditioning (i.e., recumbent stepper, treadmill).
Study NCT03428880 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: spinal morphine is done before cesarean section
Study NCT00429455 — intervention group
Intervention type: BEHAVIORAL
Intervention: Survey
Description: 3-Part Questionnaire
Study NCT01112267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol HCl/acetaminophen Extended Release
Description: Participants will receive 1 tablet containing 75 mg of tramadol HCl and 650 mg of acetaminophen, once daily on Days 1to 3, then 1 tablet twice daily on Days 4 to 7
Study NCT01112267 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive 1 matching placebo tablet once daily on Days 1 to 3, then 1 tablet twice daily on Days 4 to 7
Study NCT01112267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol HCl/acetaminophen Extended Release
Description: Participants will receive 1 or 2 tablets containing 75 mg of tramadol HCl and 650 mg of acetaminophen, twice daily on Days 8 to 28
Study NCT01112267 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Prticipants will receive 1 or 2 matching placebo tablet once daily on Days 1 to 3, then 1 tablet twice daily on Days 8 to 28
Study NCT00212355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPC-02
Description: zinc acetate
Study NCT01229670 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: * 1.exercise(Aerobic interval training (AIT)): training with 90% of VO2 peak and 40% of VO2 peak cycle for total 30 minutes exercise time~* 2.exercise(moderate continuous training (MCT)):training with 60% of VO2peak for 30 min
Study NCT03886077 — intervention group
Intervention type: DRUG
Intervention: glecaprevir/pibrentasivir
Description: 12 weeks of oral open label glecaprevir/pibrentasivir (Dose 3 tablets daily per package label).
Study NCT01065480 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Live teleconference supervision
Description: Participants receive live teleconference supervision during a session with a client on their use of Motivational Interviewing (MI) in the session. MI is a directive, client-centered counseling style for eliciting behavior change by helping clients to explore and resolve ambivalence. Compared with nondirective counselling, it is more focused and goal-directed. The examination and resolution of ambivalence is its central purpose, and the counselor is intentionally directive in pursuing this goal.
Study NCT03428880 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quadratus lumborum block
Description: a US Block QLB is done after surgery
Study NCT01065480 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Taped Review Supervision
Description: Participants audio record a session with a client and receive supervision after the session on their use of Motivational Interviewing during the session.
Study NCT01442558 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Bupivacaine 5 mg/cc with adrenaline 5 mcg/cc will be injected with complete spread of the drug around nerves.
Study NCT04308473 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultra-processed Food Meal
Description: An ultra-processed diet challenge test utilizing 1) potatoes fried in highly refined and processed vegetable oil, including corn, soybean, or canola oil, with wheat and milk derivatives; 2) a beef patty sandwich containing processed American cheese, enriched refined flour, mold inhibitor, preservatives and oxidation/reduction additives such as ascorbic acid, potassium/calcium iodate, alpha-amylase, and azodicarbonamide; and 3) a beverage composed of carbonated water, high fructose corn syrup and caramel coloring. The ultra-processed challenge meal will be obtained from a local restaurant on the day of the challenge test.
Study NCT04308473 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole Food Meal
Description: A whole food diet challenge test utilizing 1) a side salad comprised of fresh leafy vegetables, and typical whole food toppings including fresh onion, fresh tomato, fresh carrots, and raw walnuts with a pure unrefined olive oil salad dressing; 2) a legume-based main dish including chickpeas, lentils and whole grain quinoa; 3) a fresh berry-rich smoothie beverage consisting of organic blueberries, raspberries, strawberries, bananas, and fresh orange juice. The whole food challenge meal will be made by the study team from readily available commercial foods bought from local grocery stores.
Study NCT01261468 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active SCS
Description: SCS IPG activated
Study NCT01261468 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Deactivated
Description: SCS IPG deactivated
Study NCT03254615 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: I Prefer Plain Water
Description: The students will receive four educational sessions of approximately 1 hour. These sessions will be given every 2 weeks, and some will be supervised by a nutritionist.
Study NCT02225054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: 0.5 u/kg Dexmedetomidine diluted in saline to 1 mL (single interscalene injection) Dexmedetomidine 0.5 u/kg as a single IV bolus over 30 minutes following GA induction
Study NCT02225054 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: 0.5 u/kg Dexmedetomidine diluted in saline to 1 mL (single interscalene injection) Dexmedetomidine 0.5 u/kg as a single IV bolus over 30 minutes following GA induction
Study NCT02225054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: 15 ml 0.5%
Study NCT02225054 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropivacaine
Description: 15 ml 0.5%
Study NCT02225054 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: 15 ml 0.5%
Study NCT02225054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal Saline
Description: 1 mL 0.9%
Study NCT02225054 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 1 mL 0.9%
Study NCT02225054 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline
Description: 1 mL 0.9%
Study NCT04415970 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flotation therapy sensory deprivation tank
Description: Participants will float for 60 minutes, 2 times a week for 8 consecutive weeks or alternate with sleep pod every 2 weeks for 8 weeks. All participants will wear a fitness tracker and a sleep monitoring ring worn on the finger for the duration of the study. Each session will be preceded by a short safety questionnaire and an anxiety index. Following each session, the participant will complete the index again. Participants will also complete morning and evening questionnaires and monthly questionnaires on a smartphone.
Study NCT04415970 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Pod
Description: Participants will utilize the sleep pod for 60 minutes, 2 times a week for 8 consecutive weeks or alternate with float every 2 weeks for 8 weeks. All participants will wear a fitness tracker and a sleep monitoring ring worn on the finger for the duration of the study. Each session will be preceded by a short anxiety index. Following each session, the participant will complete the index again. Participants will also complete morning and evening questionnaires and monthly questionnaires on a smartphone.
Study NCT01915329 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RSS (repetitive sensory stimulation)
Description: RSS is a high frequency electrical stimulation protocol delivered to the peripheral nerves (median and ulnar nerve) of the hand. The signals are generated by a TENS-stimulator and are conveyed to each finger of the hand via a custom-made hand-shaped device with conductive contacts at each fingertip and at the palmar base.~In case of the sham-stimulation no pulses are transmitted.
Study NCT01915329 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SHAM-RSS
Description: The same device as in the RSS intervention is used, but no electrical stimuli are transmitted.
Study NCT01072565 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SMBG to guide clinical decisions
Description: The investigator will base clinical decisions on A1c and modal day analysis of SMBG.
Study NCT01072565 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SMBG and CGM
Description: The investigator will base clinical decisions on A1c, modal day analysis of SMBG and CGM data.
Study NCT01993836 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Total intravenous anesthesia with propofol
Study NCT01993836 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia with isoflurane
Study NCT04707547 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: immunotherapy with Nivolumab
Description: After subjects had received radiofrequency ablation for two weeks, they were performed by immunotherapy with Nivolumab 200mg.
Study NCT04707547 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency Ablation
Description: The most commonly used local ablation is radiofrequency ablation. In this operation, a radio frequency probe is used to insert the liver cancer under ultrasound or computer tomography guidance, and then the radio frequency waves generated by the current oscillations locally heat the high temperature, causing the liver cancer cells to die.
Study NCT01528540 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This group will include placebo.
Study NCT01528540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antioxidant plus Pregabalin
Description: This group will contain combination of antioxidant cocktail and pregabalin
Study NCT03707587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M7824
Description: Patients will receive 1200 mg intravenous (IV) of M7824 on day 1 of a 14 day cycle, every other week, for up to 12 weeks total treatment (6 cycles).
Study NCT00540423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-497115-GR 12.5mg
Description: SB-497115-GR 12.5mg tablet once a day
Study NCT03857347 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychoeducation Group for FND
Description: he intervention is a psychoeducation based group.
Study NCT00672113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalat (Nifedipine, BAYA1040)
Description: Nifedipine GITS 30 mg followed by Coracten 30 mg then back to nifedipine GITS 30 mg
Study NCT00672113 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Coracten
Description: Coracten 30 mg followed by nifedipine GITS 30 mg then back to Coracten 30 mg
Study NCT04057989 — intervention group
Intervention type: DRUG
Intervention: ketamine
Study NCT01197001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine plus Losartan
Description: Amlodipine/Losartan low dose
Study NCT01197001 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine, Losartan
Description: Amlodipine, Losartan
Study NCT03539809 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-Amino Acids
Description: 6 different ratios of the Branched-chain Amino Acids (BCAA) will be tested for 8 hours each.
Study NCT02288377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lanreotide
Description: Patients will receive lanreotide 120 mg every 28 days until disease progression
Study NCT02288377 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02217072 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: School intervention
Description: A school-based intervention that builds on the promising Swedish programme SkolFam, but is adapted to a Danish school context. The two main components of the programme are a) comprehensive assessment of the child, involving testing of the child's cognitive and academic abilities and difficulties as well as an evaluation of the child's behaviour, school-related social relations and well-being, and b) a systematic and individually targeted intervention plan, made in collaboration between a psychologist, the teachers, and a special educational teacher at the school (e.g., the reading counsellor).
Study NCT02217072 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parents as Tutors
Description: A home-based intervention, comprising a structured tutoring programme that allows foster parents to systematically support the foster child's school performance. Foster parents will attend an introductory tutor training seminar at which they will be introduced to relevant theory on learning and counselled on tutoring practice. The intervention itself is designed to provide approximately three hours per week of individual home-based tutoring for a period of 40 weeks.
Study NCT02945722 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Decolonization
Description: Decolonization schedule associate the use of mupirocin nasal ointment 3 times a day and chlorhexidine bath once a day for 5 days. Screening of persistent carriers will be done every 3 months
Study NCT04156516 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HEART
Description: sexual health intervention
Study NCT04156516 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HealthyMinds
Description: Growth mindsets of personality and mental health
Study NCT00320359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous topotecan/cisplatin
Description: Topotecan 1 mg/m2 should be administered intravenously over a period of 30 minutes on days 1-5. Then a 30 minute saline flush should be administered followed by the cisplatin on day 5.~Cisplatin 75 mg/m2 given as an intravenous infusion at the rate of 1 mg/min on day 5 after topotecan.
Study NCT00320359 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous etoposide/cisplatin
Description: Cisplatin 75 mg/m2 given as an intravenous infusion at the rate of 1 mg/min on day 1. Cisplatin should be given simultaneously to post-hydration to ensure a high volume fluid.~Etoposide 100 mg/m2 should be administered after cisplatin intravenously over a period not less than 30 minutes on days 1 -3.
Study NCT01633580 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: corifollitropin alfa
Description: long acting FSH
Study NCT01633580 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: corifollitropin alfa
Description: long acting FSH
Study NCT01329835 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle counseling
Description: 4 prenatal sessions based on principles of motivational interviewing and positive reinforcement
Study NCT01329835 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: brochure
Description: brochure given after randomization
Study NCT00634270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: This phase II study will evaluate children and adults with neurofibromatosis type-1 (NF1) and plexiform neurofibromas treated with sirolimus. It is divided in two strata. The first stratum will evaluate time to progression (TTP) in children and adults with NF1 and progressive plexiform neurofibromas with the potential to cause significant morbidity treated with sirolimus. The second stratum will evaluate objective radiographic response to sirolimus in children and adults with NF1 and inoperable plexiform neurofibromas with the potential to cause significant morbidity that do not have documented progression of the PN at time of trial entry.
Study NCT02254239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Given IV
Study NCT02254239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Given PO
Study NCT02254239 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02254239 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT02945722 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No decolonization
Description: Screening of persistent carriers in this arm will be done every 3 months
Study NCT02702349 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: penicillin test
Description: children are tested for penicillin allergy and then challenged with penicillin P.O.
Study NCT03750162 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VDW Ultra
Description: supplementary disinfection technique
Study NCT03750162 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AMD picasso
Description: supplementary disinfection technique
Study NCT03750162 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ProtaperNext X3 gutta-percha
Description: supplementary disinfection technique
Study NCT01928030 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant human hyaluronidase
Description: Given SC
Study NCT03048448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fevipiprant
Description: Single 450mg dose
Study NCT01635569 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group-based family cognitive-behavioural therapy
Description: Baseline and post-12 sessions
Study NCT01635569 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Waitlist
Description: Baseline and post-12 sessions
Study NCT03096028 — intervention group
Intervention type: OTHER
Intervention: maternal vitamin B12 folate level during pregnancy
Description: Maternal Vitamin B12 and folate level at 18\&28 weeks of pregnancy is the primary exposure of interest
Study NCT04334148 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: oral self administered tablet
Study NCT04334148 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: oral self administered tablet
Study NCT02167555 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator
Description: Wild Blueberry Beverage
Study NCT02167555 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Placebo Beverage
Study NCT00538733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalomid
Description: Cycles 1-4~• Thalidomide (50mg daily for days 1-7, thereafter 100mg daily for days 8-28 of the first 28 day cycle. Thalidomide will then be given at 100mg/daily for days 1-28 for each subsequent cycle)